FDA Panel Votes 8 to 6 To Expand Bpc-157 Compounding, Lifts Hims & Hers 7 Percent
An FDA advisory panel voted 8 to 6 to recommend adding the peptide BPC-157 to the list of bulk substances used by 503A compounding pharmacies, expanding potential access to the compound through licensed pharmacies without requiring a new drug application.
Telehealth firms including Hims & Hers Health and Noom lobbied the panel to legalize a handful of popular peptides while calling for stricter oversight and a dedicated system to track side effects. The recommendation does not constitute final approval; the FDA must still propose a rule, process public comments, and issue a final determination, a regulatory process that typically takes a year or longer.
From the sources (18 posts)
@thelonginvestPeptides
@thelonginvest$HIMS HERE WE GO
@thelonginvestPeptides $HIMS
@wallstengine$HIMS & Hers shares are trading higher after an FDA advisory panel recommended adding BPC-157 to the 503A compounding list, potentially widening access through licensed pharmacies.
@thelonginvestI can already see the messages coming in ‘Is it too late to buy $HIMS?’ No
@thelonginvestRT @himshouse: 🚨 FDA PEPTIDE PANEL VOTES 'YES' ON BPC-157 8 YES 6 NO 1 ABSTAIN $HIMS
@thelonginvest$HIMS It was always about peptides
@maxmarchioneVoting on BPC-157 at the FDA peptide hearing is happening right now
@stocksavvyshay$HIMS jumps more than 7% after an FDA panel recommends adding BPC-157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer acquisition engine. http
@thelonginvest$HIMS to $100 $ASTS to $360 $OSCR to $66 $UNH to $600 $ZETA to $66 $GRRR to $100 $ADUR to $40 $BABA to $360 $ETH $9200 There’s your portfolio Weather any storm Sit back and relax
@polymarketmoneyBREAKING: Hims & Hers scores a major win as an FDA panel backs BPC-157 for the 503A compounding list.
@maxmarchioneThe FDA peptide panel just voted YES on BPC-157. The peptide era is here.
@vestexchange$HIMS is up around 6% today, rebounding from a three-session slide ahead of the FDA's July 24 advisory hearing on compounded peptides, the key near-term item for its weight-loss and wellness offering. Recent target hikes from BofA, Canacco
@businessTelehealth companies including Hims & Hers Health and Noom urged a panel of experts to recommend legalizing a handful of popular peptides, while calling for more oversight and the creation of a system to report side effects https://t.co
@maxmarchioneThe panel just voted yes on KPV as well. KPV is a three-amino-acid fragment of α-MSH studied for its anti-inflammatory effects, particularly in the gut and skin. A meaningful result for one of the more interesting peptides in this categor
@ftFDA panel supports access to peptides over scientist objections
@maxmarchioneThe FDA peptide panel voted yes on BPC-157 and KPV, but many people are confused about what "yes" means. A "yes" vote is not FDA approval. It recommends adding these peptides to the bulk substances list used by traditional compounding pha
@maxmarchioneTB-500 just got the favorable vote. It's arguably the second biggest peptide on today’s agenda, behind only BPC-157 and now both halves of the Wolverine Stack have made it through the panel. A huge day for peptides.